top of page
Mablink Bioscience aims to dramatically improve the efficacy of ADC against cancer
is to build a pipeline of novel antibody-drug conjugates with the potential to transform the paradigm in solid tumors treatment over the next 4 years.
Mablink’s proprietary hydrophilic drug-linker technology, PSARLink™, enables the design of homogeneous, plasma-stable, next generation ADCs with high DAR (drug-to-antibody ratio) while maintaining excellent pharmacological properties and tolerability.
Our team is comprised of experts in biomedical engineering, medicinal organic chemistry, bioconjugation, pharmacology, antibody-drug conjugates, target validation and antibody development, and drug development with successful experience in development of innovative oncology immunotherapies.
bottom of page